Mo. Code Regs. Ann. tit. 19, § 20-20.020
PURPOSE: This rule designates the diseases, disabilities, conditions, and findings that must be reported to the local health authority or the Department of Health and Senior Services. It also establishes when they must be reported.
PUBLISHER’S NOTE: The secretary of state has determined that the publication of the entire text of the material which is incorporated by reference as a portion of this rule would be unduly cumbersome or expensive. This material as incorporated by reference in this rule shall be maintained by the agency at its headquarters and shall be made available to the public for inspection and copying at no more than the actual cost of reproduction. This note applies only to the reference material. The entire text of the rule is printed here.
(1) The diseases within the immediately reportable disease category pose a risk to national security because they: can be easily disseminated or transmitted from person to person; result in high mortality rates and have the potential for major public health impact; might cause public panic and social disruption; and require special action for public health preparedness. Immediately reportable diseases or findings shall be reported to the local health authority or to the Department of Health and Senior Services immediately upon knowledge or suspicion by telephone (1 (800) 392-0272), facsimile, or other rapid communication. Immediately reportable diseases or findings are—
(A) Selected high priority diseases, findings or agents that occur naturally, from accidental exposure, or as the result of a bioterrorism event: Anthrax Botulism Paralytic poliomyelitis Plague Rabies (Human) Ricin toxin Severe Acute Respiratory syndromeassociated Coronavirus (SARS-CoV) Disease Smallpox Tularemia (suspected intentional release) 19 CSR 20-20
Viral hemorrhagic fevers, suspected
intentional (e.g., Viral hemorrhagic fever diseases: Ebola, Marburg, Lassa, Lujo, new world Arenavirus (Guanarito, Machupo, Junin, and Sabia viruses), or Crimean-Congo);
(2) Reportable within one (1) day diseases or findings shall be reported to the local health authority or to the Department of Health and Senior Services within one (1) calendar day of first knowledge or suspicion by telephone, facsimile, or other rapid communication. Reportable within one (1) day diseases or findings are—
(A) Diseases, findings or agents that occur naturally, or from accidental exposure, or as a result of an undetected bioterrorism event: Animal (mammal) bite, wound, humans Brucellosis Cholera Dengue virus infection Diphtheria Glanders (Burkholderia mallei) Haemophilus influenzae, invasive disease Hantavirus pulmonary syndrome Hemolytic uremic syndrome (HUS), postdiarrheal Hepatitis A Influenza-associated mortality Influenza-associated public and/or private school closures Lead (blood) level greater than or equal to forty-five micrograms per deciliter (≥45 μg/dl) in any person Measles (rubeola) Melioidosis (Burkholderia pseudomallei) Meningococcal disease, invasive Novel Influenza A virus infections, human Outbreaks (including nosocomial) or epidemics of any illness, disease, or condition that may be of public health concern, including any illness in a food handler that is potentially transmissible through food Pertussis Poliovirus infection, nonparalytic SENIOR SERVICES
Q fever (acute and chronic) Rabies (animal) Rubella, including congenital syndrome Shiga toxin-producing Escherichia coli
(STEC) Shiga toxin positive, unknown organism Shigellosis Staphylococcal enterotoxin B Syphilis, including congenital syphilis T-2 mycotoxin Tetanus Tuberculosis disease Tularemia (all cases other than suspected intentional release) Typhoid fever (Salmonella typhi) Vancomycin-intermediate Staphylococcus aureus (VISA), and Vancomycin-resistant Staphylococcus aureus (VRSA) Venezuelan equine encephalitis virus neuroinvasive disease Venezuelan equine encephalitis virus nonneuroinvasive disease Viral hemorrhagic fevers other than suspected intentional (e.g., Viral hemorrhagic fever diseases: Ebola, Marburg, Lassa, Lujo, new world Arenavirus (Guanarito, Machupo, Junin, and Sabia viruses), or Crimean-Congo) Yellow fever;
(HIV) infection, Stage 3 Babesiosis California serogroup virus neuroinvasive disease California serogroup virus non-neuroinvasive disease Campylobacteriosis Carbon monoxide exposure CD4+ T cell count and percent Chancroid Chemical poisoning, acute, as defined in the most current ATSDR CERCLA Priority List of Hazardous Substances; if terrorism is suspected, refer to subsection (1)(B) Chlamydia trachomatis, infections Coccidioidomycosis Creutzfeldt-Jakob disease Cryptosporidiosis Cyclosporiasis Eastern equine encephalitis virus neuroinvasive disease Eastern equine encephalitis virus nonneuroinvasive disease Ehrlichiosis/Anaplasmosis (Ehrlichia chaffeensis infection, Ehrlichia ewingii infection, Anaplasma phagocytophilum infection, and Ehrlichiosis/Anaplasmosis, human, undetermined) Giardiasis Gonorrhea Hansen’s disease (Leprosy) Heavy metal poisoning including, but not limited to, arsenic, cadmium, and mercury Hepatitis B, acute Hepatitis B, chronic Hepatitis B surface antigen (prenatal HBsAg) in pregnant women Hepatitis B Virus Infection, perinatal (HBsAg positivity in any infant aged equal to or less than twenty-four (≤24) months who was born to an HBsAg-positive mother) Hepatitis C, acute Hepatitis C, chronic Human immunodeficiency virus (HIV) infection, exposed newborn infant (i.e., newborn infant whose mother is infected with HIV) Human immunodeficiency virus (HIV) infection, including any test or series of tests used for the diagnosis or periodic monitoring of HIV infection. For series of tests which indicate HIV infection, all test results in the series (both positive and negative) must be reported. Human immunodeficiency virus (HIV) infection, including any negative, undetectable, or indeterminate test or series of tests used for the diagnosis or periodic monitoring of HIV infection conducted within one hundred eighty (180) days prior to the test result used for diagnosis of HIV infection Human immunodeficiency virus (HIV) infection, pregnancy in newly identified or pre-existing HIV positive women Public Health
Human immunodeficiency virus (HIV)
infection, test results (including both positive and negative results) for children less than two (2) years of age whose mothers are infected with HIV Human immunodeficiency virus (HIV) infection, viral load measurement (including undetectable results) Hyperthermia Hypothermia Lead (blood) level less than forty-five micrograms per deciliter (<45 μg/dl) in any person Legionellosis Leptospirosis Listeriosis Lyme disease Malaria Methemoglobinemia, environmentally induced Mumps Non-tuberculosis mycobacteria (NTM) Occupational lung diseases including silicosis, asbestosis, byssinosis, farmer’s lung, and toxic organic dust syndrome Pesticide poisoning Powassan virus neuroinvasive disease Powassan virus non-neuroinvasive disease Psittacosis Rabies Post-Exposure Prophylaxis (Initiated) Respiratory diseases triggered by environmental contaminants including environmentally or occupationally induced asthma and bronchitis Rickettsiosis, Spotted Fever Saint Louis encephalitis/virus neuroinvasive disease Saint Louis encephalitis virus non-neuroinvasive disease Salmonellosis Streptococcus pneumoniae, Invasive disease (IPD-Invasive Pneumococcal Disease) Streptococcal toxic shock syndrome (STSS) Toxic shock syndrome, non-streptococcal Trichinellosis Tuberculosis infection Varicella (Chickenpox) Varicella deaths Vibriosis (non-cholera Vibrio species infections) West Nile virus neuroinvasive disease West Nile virus non-neuroinvasive disease Western equine encephalitis virus neuroinvasive disease Western equine encephalitis virus nonneuroinvasive disease Yersiniosis.
(6) A physician, physician’s assistant, nurse, hospital, clinic, or other private or public institution providing diagnostic testing, screening or care to any person with any disease, condition, or finding listed in sections (1)–(4) of this rule or who is suspected of having any of these diseases, conditions, or findings, shall make a case report to the local health authority or the Department of Health and Senior Services, or cause a case report to be made by their designee, within the specified time.
(7) Except for influenza, laboratory-confirmed and Varicella (Chickenpox); a case report as required in section (6) of this rule shall include the patient’s name, home address with zip code, date of birth, age, sex, race, home phone number, name of disease, condition or finding diagnosed or suspected, the date of onset of the illness, name and address of the treating facility (if any) and the attending physician, any appropriate laboratory results, name and address of the reporter, treatment information for sexually transmitted diseases, and the date of report.
(12) The following material is incorporated into this rule by reference:
(13) Each hospital and ambulatory surgical center shall report on a quarterly basis antibiogram data for infection, not colonization, from all body sites monitored by that health care facility. Antibiogram data to be reported shall include nosocomial methicillin sensitive Staphylococcus aureus (S. aureus), nosocomial S. aureus, nosocomial vancomycin sensitive enterococci, and nosocomial enterococci isolates. Data shall be reported directly to the Department of Health and Senior Services. Reporting shall include only a patient’s first diagnostic nosocomial isolate per admission of Staphylococcus aureus (S. aureus) and enterococci and the isolates corresponding methicillin or vancomycin sensitivity; irrespective of location or of other antimicrobial sensitivity(ies). Intermediate methicillin or vancomycin sensitivity shall be reported as resistant (i.e., methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant enterococci (VRE), respectively).
(B) Aggregate antibiogram data for patients’ non-duplicative isolates, per admission, of nosocomial MRSA and VRE infections shall reflect susceptibility patterns and shall be reported as the:
aureus sensitive to methicillin (oxacillin, etc.);
aureus;
enterococci sensitive to vancomycin; and
rococci.
AUTHORITY : sections 192.006, 210.040, and 210.050, RSMo 2000, and section 192.020, RSMo Supp. 2013.* This rule was previously filed as 13 CSR 50-101.020. Original rule filed July 15, 1948, effective Sept. 13, 1948. Amended: Filed Sept. 1, 1981, effective Dec. SENIOR SERVICES 11, 1981. Rescinded and readopted: Filed Nov. 23, 1982, effective March 11, 1983. Emergency amendment filed June 10, 1983, effective June 20, 1983, expired Sept. 10, 1983. Amended: Filed June 10, 1983, effective Sept. 11, 1983. Amended: Filed Nov. 4, 1985, effective March 24, 1986. Amended: Filed Aug. 4, 1986, effective Oct. 11, 1986. Amended: Filed June 3, 1987, effective Oct. 25, 1987. Emergency amendment filed June 16, 1989, effective June 26, 1989, expired Oct. 23, 1989. Amended: Filed July 18, 1989, effective Sept. 28, 1989. Amended: Filed Nov. 2, 1990, effective March 14, 1991. Emergency amendment filed Oct. 2, 1991, effective Oct. 12, 1991, expired Feb. 8, 1992. Amended: Filed Oct. 2, 1991, effective Feb. 6, 1992. Amended: Filed Jan. 31, 1992, effective June 25, 1992. Amended: Filed Aug. 14, 1992, effective April 8, 1993. Amended: Filed Sept. 15, 1994, effective March 30, 1995. Amended: Filed Sept. 15, 1995, effective April 30, 1996. Emergency amendment filed June 1, 2000, effective June 15, 2000, expired Dec. 11, 2000. Amended: Filed June 1, 2000, effective Nov. 30, 2000. Emergency amendment filed Dec. 16, 2002, effective Dec. 26, 2002, expired June 23, 2003. Amended: Filed Dec. 16, 2002, effective June 30, 2003. Amended: Filed Oct. 1, 2004, effective April 30, 2005. Amended: Filed Feb. 15, 2006, effective Sept. 30, 2006. Amended: Filed Nov. 15, 2007, effective May 30, 2008. Amended: Filed Nov. 10, 2015, effective April 30, 2016. *Original authority: 192.006, RSMo 1993, amended 1995; 192.020, RSMo 1939, amended 1945, 1951, 2004; 210.040, RSMo 1941, amended 1993; and 210.050, RSMo 1941, amended 1993.